Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referenced as Newcelx Ltd. in metadata) covers the period ending October 28, 2024. The registrant is a foreign private issuer headquartered in Zurich, Switzerland, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a corporate governance event rather than financial performance data.
Material Changes
The primary material change disclosed is the company's regaining of full compliance with Nasdaq listing requirements, as announced in a press release dated October 28, 2024.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors. The document incorporates the press release regarding Nasdaq compliance by reference into the company's active Registration Statements on Form F-3.
Investor Verification Checklist
- Verify the specific Nasdaq listing rule that was previously violated and the steps taken to achieve compliance.
- Review the full text of the press release (Exhibit 99.1) for details on the compliance timeline.
- Confirm the status of the company's active Form F-3 registration statements (File Nos. 333-282788, 333-262489, 333-268690, and 333-269220).
- Check subsequent filings for any updated financial data, as this 6-K contains none.